Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Jones Lang LaSalle Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Jones Lang LaSalle Inc trades at $324.44 (market cap $15.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Jones Lang LaSalle Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JLL | |
|---|---|---|
Market Cap | $39.89B | $15.05B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $358.66 |
52-Week Low | $278.09 | $248.95 |
Enterprise Value | $38.15B | $18.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JLL trades at $324.44, showing modest daily gains with strong technical momentum and bullish moving averages. The company demonstrates solid fundamental improvement with revenue growth to $26.12B in 2025 and consistent earnings beats. Recent news highlights significant financing deals and Fortune 500 ranking improvement, reflecting strong business execution in commercial real estate services.
JLL presents a compelling investment case with 25% upside to consensus price target of $405.50, supported by improving profitability and positive analyst sentiment. Key risks include commercial real estate market cyclicality and competitive pressures. The stock's current valuation metrics (P/E 17.45, P/S 0.58) appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
